OSS-128167

Research use only, not for human use.

OSS-128167 is a novel selective, cell permeable SIRT6 inhibitor.

OSS-128167 is a novel selective, cell permeable SIRT6 inhibitor with IC50 of 89, 1578 and 751 uM for SIRT6, SIRT1 and SIRT2, respectively; increases H3K9 acetylation and GLUT-1 expression in treated cells.

Western Blot Analysis Cell Line:BxPC3 cells Concentration:100 μM Incubation Time:0 hours, 2 hours, 6 hours, 18 hours, 24 hours Result:Increased H3K9 acetylation.RT-PCR Cell Line:HepG2.2.15 and HepG2-sodium taurocholate cotransporting polypeptide (NTCP) cells Concentration:100 μM Incubation Time:96 hours Result:Significantly decreased HBV core DNA and 3.5-Kb RNA levels.

Animal Model:Male HBV transgenic mice (6-8-week-old)Dosage:50 mg/kg Administration:Intraperitoneal injection; every 4 days; for 12 days Result:The level of HBV DNA and 3.5-Kb RNA were markedly suppressed in HBV transgenic mice.

OSS128167

Chromatin/Epigenetic

Sirtuin

SIRT6|SIRT2|SIRT1

——

——

887686-02-4

366.329

C19H14N2O6

>98% (HPLC)

DMSO: 68 mg/mL (185.6 mM); Ethanol: <1 mg/mL; Water: <1 mg/mL （ < 1 mg/ml refers to the product slightly soluble or insoluble )

C1=CC(NC(=O)C2=CC=CO2)=CC(C(=O)NC2=CC=C(O)C(C(O)=O)=C2)=C1

5-[[3-[(2-Furanylcarbonyl)amino]benzoyl]amino]-2-hydroxybenzoic acid

(-20℃)

With Ice Pack

≥ 2 years